Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Capricor Therapeutics (CAPR) EBITDA Margin (2016 - 2025)

Capricor Therapeutics has reported EBITDA Margin over the past 15 years, most recently at 189079.87% for Q1 2025.

  • Quarterly results put EBITDA Margin at 189079.87% for Q1 2025, down 18898265.0% from a year ago — trailing twelve months through Dec 2025 was 846781.91% (down 84663677.0% YoY), and the annual figure for FY2024 was 178.16%, down 8998.0%.
  • EBITDA Margin for Q1 2025 was 189079.87% at Capricor Therapeutics, down from 55.49% in the prior quarter.
  • Over the last five years, EBITDA Margin for CAPR hit a ceiling of 5.65% in Q4 2023 and a floor of 189079.87% in Q1 2025.
  • Median EBITDA Margin over the past 5 years was 338.93% (2022), compared with a mean of 15042.57%.
  • Biggest five-year swings in EBITDA Margin: soared 468432bps in 2021 and later plummeted -18898265bps in 2025.
  • Capricor Therapeutics' EBITDA Margin stood at 2303.0% in 2021, then skyrocketed by 65bps to 802.16% in 2022, then skyrocketed by 99bps to 5.65% in 2023, then tumbled by -883bps to 55.49% in 2024, then crashed by -340661bps to 189079.87% in 2025.
  • The last three reported values for EBITDA Margin were 189079.87% (Q1 2025), 55.49% (Q4 2024), and 557.8% (Q3 2024) per Business Quant data.